Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Abstract

Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.

Keywords:

• glecaprevir
• pibrentasvir
• direct-acting antiviral therapy
• hepatitis C virus

Disclosure

Dr Donald M Jensen reports grants from Abbvie, during the conduct of the study; received travel reimbursements from AASLD for attending annual meetings and visiting industry clients, outside the submitted work. The authors report no other conflicts of interest in this work.